22:39 , Jul 9, 2019 |  BC Extra  |  Company News

July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

Celgene gets option for Nimbus' HPK1 program  Celgene Corp. (NASDAQ:CELG) expanded its partnership with Nimbus Therapeutics LLC (Cambridge, Mass.) to include an option for the latter's HPK1 inhibitor to treat cancer, which Celgene can exercise...
22:34 , May 14, 2019 |  BC Extra  |  Clinical News

May 14 Clinical Quick Takes: Myovant, Solid, Minerva, Modus, Zealand

Myovant tumbles after Phase III uterine fibroid data  Myovant Sciences Ltd. (NYSE:MYOV) lost $4.39 (25%) to $12.83 Tuesday despite reporting that relugolix (TAK-385) met the primary endpoint of a better response rate than placebo in...
20:14 , Mar 29, 2019 |  BC Week In Review  |  Clinical News

Opko's diabetes therapy meets in Phase IIb

Opko said OPK88003 met the primary endpoint in a Phase IIb trial to treat adult Type II diabetics who had inadequate glucose control with metformin and/or diet and exercise. Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK)...
02:10 , Oct 20, 2018 |  BioCentury  |  Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
16:38 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Zealand's hypoglycemia candidate meets in second Phase III

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said dasiglucagon (ZP4207) met the primary endpoint in a second Phase III trial to treat severe hypoglycemia in patients with Type I diabetes. The trial is evaluating a liquid formulation...
16:44 , Jul 6, 2018 |  BC Week In Review  |  Clinical News

AZ's MEDI0382 reduces glucose and body weight in Phase IIa for Type II diabetes

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said once-daily 200 µg subcutaneous MEDI0382 significantly reduced glucose area under the curve (AUC) from 0-4 hours after a Mixed Meal Tolerance Test (MMTT) (32.8% vs....
16:59 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Zealand's hypoglycemia candidate meets in first Phase III

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said dasiglucagon (ZP4207) met the primary endpoint in a Phase III trial to treat severe hypoglycemia in patients with Type I diabetes. The trial is evaluating a liquid formulation of...
19:57 , Mar 20, 2018 |  BC Extra  |  Clinical News

Zealand's hypoglycemia candidate meets in first Phase III

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said dasiglucagon (ZP4207) met the primary endpoint in a Phase III trial to treat severe hypoglycemia in patients with Type I diabetes. The trial is evaluating a liquid formulation of...
18:11 , Mar 9, 2018 |  BC Week In Review  |  Company News

Roivants new subsidiary adds Ligand asset

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted exclusive, worldwide rights for diabetes candidate RVT-1502 (formerly LGD-6972) to the newly created Metavant Sciences subsidiary of Roivant Sciences GmbH (Basel, Switzerland). Roivant has established at least six subsidiaries, which...
23:30 , Mar 7, 2018 |  BC Extra  |  Company News

Roivant unveils new subsidiary on deal with Ligand

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted exclusive, worldwide rights for diabetes candidate RVT-1502 (formerly LGD-6972) to the newly created Metavant Sciences subsidiary of Roivant Sciences GmbH (Basel, Switzerland). Roivant has established at least six subsidiaries, which...